RecruitingPhase 2NCT04405401

Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer

Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Non Small Cell Lung Cancer: A Registry-based Phase II Randomized Trial

Sponsor

Centre hospitalier de l'Université de Montréal (CHUM)

Enrollment

68 participants

Start Date

Jan 5, 2021

Study Type

INTERVENTIONAL

Conditions

Lung Cancer Metastatic

Summary

A registry-based randomized screening phase II trial. A total of 68 patients with metastatic non small cell lung cancer on systemic therapy with oligoprogression to 1-5 extracranial lesions will be randomized using a 1:1 ratio to standard of care (begin next-line systemic therapy, best supportive care, continue current systemic line, based on treating physician decision) vs. receive stereotactic ablative radiotherapy to all oligoprogressive lesions while continuing their current systemic therapy.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study looks at whether targeted radiation (SABR/SBRT) delivered to a small number of growing tumor spots can help patients with advanced non-small cell lung cancer stay on their current treatment (such as immunotherapy or targeted therapy) longer, even when part of their cancer has started to progress. **You may be eligible if...** - You are 18 or older - You have metastatic (spread) non-small cell lung cancer - You are currently on immunotherapy or targeted therapy and only 1–5 spots (outside the brain) have started growing - The growing spots are all 5cm or smaller and in no more than 3 organs - You are in reasonably good health (able to care for yourself) **You may NOT be eligible if...** - Any growing tumor is larger than 5cm - You are pregnant or breastfeeding - Your cancer has invaded the digestive tract (esophagus, stomach, bowel) - You have spinal cord compression - A medical condition prevents you from safely receiving radiation Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONSABR

SABR to all oligoprogressive lesions + continuation of current systemic therapy

OTHERStandard of care

Patients on the standard arm will be treated as per standard of care in our institution. Treatment options could include switching to next systemic therapy line, best supportive care or continuing on current systemic therapy.

Locations(1)

Centre Hospitalier de l'Université de Montréal

Montreal, Quebec, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04405401

Related Trials

Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer

NCT054520051 location

A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain

NCT054190767 locations

Clinical Application Study of PET/CT for Differential Diagnosis of Non-small Cell Lung Cancer

NCT070261101 location

Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

NCT0507804740 locations

TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer

NCT065380121 location